IP Library Granted Patent US 8,722,619
Granted Patent B2
US 8,722,619 · App. 13/886,972 · Granted May 13, 2014

Antifungal agents and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,619
App. No.
13/886,972
Granted
May 13, 2014
Kind
B2
Abstract

The invention features echinocandin class compounds. The compounds can be useful for the treatment of fungal infections.

Claims (22)

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein said compound is an acetate salt.

3. The compound of claim 1 , wherein said compound is a chloride salt.

4. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

5. The pharmaceutical composition of claim 4 , wherein said compound is an acetate salt.

6. The pharmaceutical composition of claim 4 , wherein said compound is a chloride salt.

7. The pharmaceutical composition of claim 4 , wherein said pharmaceutical composition is formulated for oral administration.

8. The pharmaceutical composition of claim 4 , wherein said pharmaceutical composition is formulated for intravenous administration.

9. The pharmaceutical composition of claim 4 , wherein said pharmaceutical composition is formulated for topical administration.

10. The pharmaceutical composition of claim 4 , wherein said pharmaceutical composition is formulated for subcutaneous administration.

11. The pharmaceutical composition of claim 4 , wherein said pharmaceutical composition is formulated for inhalation.

12. A method of treating a fungal infection in a subject, said method comprising administering to said subject a pharmaceutical composition of claim 4 in an amount sufficient to treat said infection.

13. The method of claim 12 , wherein said pharmaceutical composition is administered orally.

14. The method of claim 12 , wherein said pharmaceutical composition is administered intravenously.

15. The method of claim 12 , wherein said pharmaceutical composition is administered topically.

16. The method of claim 12 , wherein said pharmaceutical composition is administered subcutaneously.

17. The method of claim 12 , wherein said pharmaceutical composition is administered by inhalation.

18. The method of claim 12 , wherein said pharmaceutical composition is administered to treat a blood stream infection or tissue infection in said subject.

19. The method of claim 12 , wherein said infection is selected from tinea capitis, tinea corporis, tinea pedis, onychomycosis, perionychomycosis, pityriasis versicolor, oral thrush, vaginal candidosis, respiratory tract candidosis, biliary candidosis, eosophageal candidosis, urinary tract candidosis, systemic candidosis, mucocutaneous candidosis, aspergillosis, mucormycosis, paracoccidioidomycosis, North American blastomycosis, histoplasmosis, coccidioidomycosis, sporotrichosis, fungal sinusitis, or chronic sinusitis.

20. The method of claim 12 , wherein said fungal infection is an infection of Candida albicans, C. parapsilosis, C. glabrata, C. guilliermondii, C. krusei, C. tropicalis, C. lusitaniae, Aspergillus fumigatus, A. flavus, A. terreus, A. niger, A. candidus, A. clavatus , or A. ochraceus.

21. A method of inhibiting the growth of fungi, or killing fungi, said method comprising contacting said fungi with the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2024
From: CIDARA THERAPEUTICS, INC.
To: NAPP PHARMACEUTICAL GROUP LIMITED
Reel/Frame 069163/0195 →
CHANGE OF NAME Recorded Aug 13, 2014
From: K2 THERAPEUTICS, INC.
To: CIDARA THERAPEUTICS, INC.
Reel/Frame 033532/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2014
From: SEACHAID PHARMACEUTICALS, INC.
To: K2 THERAPEUTICS, INC.
Reel/Frame 033414/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2014
From: JAMES, KENNETH DUKE, JR.; LAUDEMAN, CHRISTOPHER PATRICK
To: SEACHAID PHARMACEUTICALS, INC.
Reel/Frame 032583/0788 →